Science News
from research organizations

Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster

Date:
April 9, 2013
Source:
Public Library of Science
Summary:
A vaccine to prevent shingles may reduce by half the occurrence of this painful skin and nerve infection in older people (aged over 65 years) and may also reduce the rate of a painful complication of shingles, post-herpetic neuralgia, but has a very low uptake (only 4 percent) in older adults in the United States, according to a new study.
Share:
       
FULL STORY

Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster, but uptake in the US is low.

A vaccine to prevent shingles may reduce by half the occurrence of this painful skin and nerve infection in older people (aged over 65 years) and may also reduce the rate of a painful complication of shingles, post-herpetic neuralgia, but has a very low uptake (only 4%) in older adults in the United States, according to a study by UK and US researchers published in this week's PLOS Medicine.

The researchers, led by Sinéad Langan from the London School of Hygiene and Tropical Medicine, reached these conclusions by examining the records of 766,330 Medicare beneficiaries* aged 65 years or more between 2007 and 2009.

They found that shingles vaccine uptake was extremely low -- only 3.9% of participants were vaccinated -- but was particularly low among black people (0.3%) and among people with a low income (0.6%).

Over the study period, almost 13,000 participants developed shingles and the vaccine reduced the rate of shingles by 48% (that is, approximately half as many vaccinated individuals developed shingles as those who were not vaccinated). However, the vaccine was less effective in older adults with impaired immune systems. The authors also found that vaccine effectiveness against post-herpetic neuralgia was 59%.

The authors say: "Herpes zoster vaccination was associated with a significant reduction in incident herpes zoster and [post-herpetic neuralgia] in routine clinical use."

They continue: "Despite strong evidence supporting its effectiveness, clinical use remains disappointingly low with particularly low vaccination rates in particular patient groups."

The authors add: " The findings are relevant beyond US medical practice, being of major importance to the many countries, including the UK, that are actively considering introducing the zoster vaccine into routine practice in the near future."


Story Source:

The above post is reprinted from materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sinéad M. Langan, Liam Smeeth, David J. Margolis, Sara L. Thomas. Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study. PLoS Medicine, 2013; 10 (4): e1001420 DOI: 10.1371/journal.pmed.1001420

Cite This Page:

Public Library of Science. "Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster." ScienceDaily. ScienceDaily, 9 April 2013. <www.sciencedaily.com/releases/2013/04/130409173504.htm>.
Public Library of Science. (2013, April 9). Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2013/04/130409173504.htm
Public Library of Science. "Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster." ScienceDaily. www.sciencedaily.com/releases/2013/04/130409173504.htm (accessed July 31, 2015).

Share This Page: